Incyte, Syndax get FDA OK of graft-v-host therapy

– U.S. launch expected in early February –

– Niktimvo is the first and only approved treatment for chronic GVHD that targets CSF-1R to reduce the drivers of inflammation and fibrosis –

– Pivotal data from the AGAVE-201 trial supporting FDA approval show treatment with Niktimvo resulted in durable responses across all organs studied and patient subgroups –

https://www.marketscreener.com/quote/stock/INCYTE-CORPORATION-9675/news/Incyte-and-Syndax-Announce-U-S-Food-and-Drug-Administration-FDA-Approval-of-Niktimvo-axatilim-48777150/